Minvasys: Tailoring the Stent to Fit the Lesion in Bifurcations

Bifurcated lesions remain one of the most challenging unmet clinical needs facing interventional cardiologists, even with current drug-eluting stents. Here's how one small company is challenging bigger players in this promising market by developing polymer-free DES designed specifically for these difficult bifurcated lesions.

For all the success that drug-eluting stents (DES) have had in treating restenosis (late-stent thrombosis safety issues notwithstanding), certain types of vascular disease remain challenges for interventional cardiologists, even with the current-generation of DES. These include chronic total occlusions, and small and tortuous diseased vessels. One of the largest areas of unmet clinical need exists in patients with bifurcated lesions, where restenosis occurs at a point at which vessels divide into a Y-shape, with a side branch that is more than 2 mm in diameter coming off the main vessel.

Bifurcated lesions occur in an estimated 20 to 30% of all percutaneous coronary interventions (PCI). They are currently treated largely...

More from Global Vision

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.